Joanne M Donovan

7261880, Aug 28, 2007

Apr 17, 2002

10/125701

Steven K. Burke - Sudbury MA, US
Joanne M. Donovan - Needham MA, US

Genzyme Corporation - Cambridge MA

A61K 31/74
A61K 31/785

424 7831, 424 7835

The invention relates to a method for treating Syndrome X, or inhibiting the onset of symptoms of Syndrome X in a patient, and includes administering a therapeutically effective amount of a salt of at least one alkylated and cross-linked polymer, or a copolymer thereof, the polymer salt formed as a product of the reaction of one or more polymers, or salts and copolymers thereof, having a repeat unit that is essentially:.

20070098678, May 3, 2007

Jun 26, 2006

11/475385

Hitesh Bhagat - Wayland MA, US
Joanne Donovan - Needham MA, US
William Braunlin - Arlington MA, US
Robert Sacchiero - Hudson MA, US

A61K 31/785
A61K 9/20

424078270, 424464000

Tablets, capsules, sachets, or papers having one or more aliphatic amine polymers allow for the targeted release of the polymers at a specific region of the gastrointestinal tract, especially the small intestine. These tablets, capsules, sachets, or papers are useful in a method for lowering cholesterol in a mammal in need thereof. The tablet includes a tablet core having an aliphatic amine polymer, and an enteric coating for the core. The capsule, sachet or paper includes a plurality of beads where the beads have a bead core having an aliphatic amine polymer, an enteric coating therefor and optionally a water-soluble coating.

20070286841, Dec 13, 2007

Apr 25, 2007

11/789698

Steven Burke - Sudbury MA, US
Joanne Donovan - Needham MA, US

A61K 31/785
A61P 3/10

424078350

A method for treating hyperglycemia and/or reducing serum glucose levels in a patient that includes administering to the patient a therapeutically effective amount of an amine polymer is disclosed. In one embodiment, the amine polymer is aliphatic. Examples of polymers useful in an embodiment of the invention include sevelamer hydrogen chloride and colesevelam. The invention includes the use of amine polymers such as a cross-linked polymer characterized by a repeat unit having the formula: and salts and copolymers thereof, where n is a positive integer and x is zero or an integer between 1 and about 4. Also described is a use, for the manufacture of a medicament, of a polymer that lowers serum glucose.

20080085872, Apr 10, 2008

Jun 28, 2007

11/823853

Steven Burke - Sudbury MA, US
Joanne Donovan - Needham MA, US

A61K 31/336
A61K 31/675
A61K 31/70

514052000, 514475000, 514089000

The invention relates to a method for treating Syndrome X, or inhibiting the onset of symptoms of Syndrome X in a patient, and includes administering a therapeutically effective amount of a salt of at least one alkylated and cross-linked polymer, or a copolymer thereof, the polymer salt formed as a product of the reaction of one or more polymers, or salts and copolymers thereof, having a repeat unit that is essentially: where n is a positive integer and each R, independently, is H or a C-Calkyl group; at least one aliphatic alkylating agent; and a cross-linking agent. Long term administration of the cross-linked polyamine salts of the invention increases HDL levels and decreases LDL levels in patients. The invention also provides for administration of the polymer salt colesevelam, in combination with an HMG-CoA reductase inhibitor; the combined administration is effective in further lowering serum total-cholesterol and LDL-cholesterol levels beyond that achieved by either agent alone.

7229613, Jun 12, 2007

Apr 17, 2002

10/125700

Steven K. Burke - Sudbury MA, US
Joanne M. Donovan - Needham MA, US

Genzyme Corporation - Cambridge MA

A61K 31/785

424 7835, 424 7836, 424 7837

A method for treating hyperglycemia and/or reducing serum glucose levels in a patient that includes administering to the patient a therapeutically effective amount of an amine polymer is disclosed. In one embodiment, the amine polymer is aliphatic. Examples of polymers useful in an embodiment of the invention include sevelamer hydrogen chloride and colesevelam. The invention includes the use of amine polymers such as a cross-linked polymer characterized by a repeat unit having the formula:.

20150352094, Dec 10, 2015

Jan 7, 2014

14/759625

- Cambridge MA, US
Chi B. Vu - Boston MA, US
Jill C. Milne - Brookline MA, US
Michael R. Jirousek - Cambridge MA, US
Joanne Donovan - Needham MA, US

A61K 31/4406
A61K 31/575
A61K 45/06

The invention relates to fatty acid niacin conjugates; compositions comprising an effective amount of a fatty acid niacin conjugate; methods for treating or preventing an metabolic disease comprising the administration of an effective amount of a fatty acid niacin conjugate, and methods for treating or preventing an metabolic disease comprising the administration of an effective amount of a fatty acid niacin conjugate and another therapeutic agent.